Sugi Predict

Sugi Predict / Compounds / SCHEMBL4090598

SCHEMBL4090598

SCHEMBL4090598

CS(=O)(=O)N1CC2C(C1)C2Nc1ncc2cc(-c3ccccc3Cl)c(=O)n(-c3ccc(F)cc3)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 2/20 0.47
▸ LCK P06239 1/20 0.47
▸ RIPK2 O43353 3/20 0.44
▸ NOD2 Q9HC29 3/20 0.44
▸ ACVR1 Q04771 1/20 0.44
▸ PAK1 Q13153 2/20 0.43
▸ SIK1 P57059 1/20 0.42
▸ SIK2 Q9H0K1 1/20 0.42
▸ SIK3 Q9Y2K2 1/20 0.42
▸ TNK2 Q07912 3/20 0.42
▸ ABL1 P00519 2/20 0.42
▸ FGFR1 P11362 2/20 0.42
▸ EGFR P00533 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ KIT P10721 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ CCND1 P24385 5/20 0.41
▸ CCNE1 P24864 5/20 0.41
▸ CDK2 P24941 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4098651 0.90 MAPK14 (0.43) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL13849301 0.88 MAPK14 (0.47) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4089107 0.87 MAPK14 (0.46) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4094749 0.86 MAPK14 (0.48) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4089655 0.86 LCK (0.63) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4088404 0.86 MAPK14 (0.45) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4084691 0.85 MAPK14 (0.44) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4091050 0.84 MAPK14 (0.44) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4089699 0.84 CNR1 (0.47) MAPK14LCKRIPK2NOD2ACVR1
SCHEMBL4084205 0.84 CCND1 (0.54) MAPK14LCKCCND1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US claimed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 — — EP claimed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 — — WO claimed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 — — EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 MAPK14 3185/4885LCK 568/4885RIPK2 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.